MENU

Senseonics and Beta Bionics: iLet CGM Integration and Timeline

MedTech Dive USA
Overview
Senseonics and Beta Bionics have entered a non-monetary partnership to integrate the Eversense 365 implantable CGM with the iLet automated insulin delivery (AID) system. Targeted for a Q4 2026 launch, the deal focuses on technical interoperability to move Eversense out of a niche market.
In Depth

Key Findings

Senseonics and Beta Bionics have agreed to integrate their flagship diabetes devices in a deal that involves no equity investment, no minimum purchase commitments, and no exclusivity payments. The partnership relies entirely on the technical ability of the two devices to work together. The integration is intended to expand the reach of the Eversense 365 implantable sensor by pairing it with the iLet automated insulin delivery system, with a launch targeted for Q4 2026.

Technical Details

The iLet system utilizes an adaptive algorithm that manages insulin doses based on user input regarding meal size, eliminating the need for carbohydrate counting. The Eversense 365 sensor provides glucose readings every five minutes. Senseonics states that the iLet algorithm will not require retuning because sensor lag is already accounted for in the reporting of glucose values. The integration is software-only, requiring a firmware update to the iLet, and therefore does not require a new FDA filing.

Background & Context

The Eversense 365 differentiates itself from traditional CGMs by lasting up to a year under the skin, compared to roughly 15 days for standard sensors. While the insertion requires a clinician visit, it eliminates the need for frequent replacements and prevents compression lows. Senseonics is guiding toward 2026 revenue of $58 million to $62 million. This is the company’s second pump partnership, following an April 2025 agreement with Sequel Med Tech’s Twiist system.

Significance & Outlook

The deal reflects a strategic shift toward interoperability, as patients increasingly expect to pair preferred sensors with preferred pumps. Beta Bionics will continue to support sensors from Abbott and Dexcom. However, several uncertainties remain: whether payers will cover both devices simultaneously, the expected sales volume post-launch, and whether Senseonics can secure partnerships with larger pump makers such as Insulet or Tandem to move beyond a niche market position.

Source: https://finance.biggo.com/news/0749cca54d322e52

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC